To include your compound in the COVID-19 Resource Center, submit it here.

CXCR2 antagonists in breast cancer

A team at the Memorial Sloan-Kettering Cancer Center has shown that CXC chemokine receptor 2 antagonists sensitized tumors to chemotherapy in mouse models of metastatic breast cancer.1 The team is working on additional preclinical studies with the intention of moving the antagonists into clinical trials for breast cancer.

Resistance to chemotherapy often occurs in breast cancer as a result of a small percentage of cancer cells that develop a survival advantage and show a more aggressive, metastatic phenotype.

The challenge has been identifying the factors that confer the survival advantage and figuring out how to target them in combination with chemotherapy to prevent resistance, tumor relapse and metastasis.

In 2005, the Sloan-Kettering team, led by Joan Massagué, found that expression of chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA) and CXCL2 (MIP2) on breast cancer cells was

Read the full 1342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers